Notice
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Will we be able to answer the question of HDL as a therapeutic target after the CETP inhibitor trials? (Eric STROES)
- document 1 document 2 document 3
- niveau 1 niveau 2 niveau 3
Descriptif
MODIGLIANI Workshop 5 - Saturday December 1st, 2012
THE ATHEROSCLEROSIS TRIALISTS FORUM
Chairpersons: Wolfgang KOENIG, Ulm, GER - Anthony WIERZBICKI, London, GBR
Webcast: Tabassome SIMON, Paris, FRA
Will new compounds be able to reduce the residual risk in high risk patients when treatment targets based on new ESC guidelines have been achieved (e.g. LDL-C < 70mg/dl)?
Despite widespread early intervention in acute coronary syndromes and complete revascularization of stenotic lesions complemented by aggressive polypharmacotherapy, still a high percentage of patients develop a secondary event.
This has been shown in various registries and recent data from the GRACE registry have suggested that we grossly underestimate long-term risk in these patients. Thus, despite all our current efforts there is room for improvement.
➢ A very active clinical research programme is delivering an important number of new potential therapeutic targets that
may be ready for trial testing.
• Can OMICS technology help us out here in terms of new specific biomarkers taking advantage of the proteome, metabolome or the transcriptome?
• What is the relevance of Mendelian Randomisation studies to investigate the potential causal role of biomarkers in the pathophysiology of disease and to identify and select new drug biotargets.
➢ One major question relates to the value of biomarker-guided and/or risk guided therapy and how to design appropriate trials to test these therapeutic strategies. Should therapy be targeted to patients with specific biomarkers profiles? e.g. low HDL, high inflammatory burden (elevated CRP), high Lp-PLA2 activity etc.?
➢ A fairly large number of lipid-associated new targets or targets reflecting other pathways of the complex atherosclerotic process are being evaluated in mechanistic imaging studies but also in large randomised controlled clinical trials looking for important cardiovascular endpoints. In all of these trials the standard of care is much better than seen in the real world situation. Thus, the question arises, whether these additional compounds will lead to a clinically significant reduction in cardiovascular events on top of optimal standard care.
Trials (Interventions)
➢ CETP inhibitors: dalcetrapib, anacetrapib, evacetrapib (DAL-Outcomes I, DAL-Outcomes II, DEFINE, REVEAL, evacetrapib, ApoA1 mimetics, ApoA1 Milano, AIM-HIGH, HPS-Thrive)
➢ Directly augmenting apo A-I: Intravenous apo A-I therapy, Recombinant apo A-I Milano/phospholipids (ETC-216), Purified native apo A-I/phospholipids (CSL-111/112)
➢ Oral upregulators of endogenous apo A-I production RVX-208: ASSURE, SUSTAIN
➢ Phospholipase inhibitors: VISTA-16, SOLID, STABILITY
➢ Anti-inflammatory therapy: CANTOS (IL-1β antibody), CIRT (MTX), Anakinra (IL1 RA), IL-6 RA (Taxilicumab)
➢ New LDL-lowering compounds: PCSK9 inhibitors, apoB antisense, ISIS
Session program:
Will we be able to answer the question of HDL as a therapeutic target after the CETP inhibitor trials?
Speaker: Eric STROES, Amsterdam, NED
Discussant: Robert ROSENSON, New York, USA
Identifying new targets: The value of omics and mendelian randomization studies
Speaker: Juan Pablo CASAS, London, GBR
Identifying new targets: Monoclonal Antibody Inhibitor of PCSK9
Speakers: Wolfgang KOENIG, Ulm, GER - Robert SCOTT, Amgen, USA
Thème
Documentation
Liens
Dans la même collection
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Joer…
KOECK Jean-Louis
MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is hear…
DELIARGYRIS Efthymios
MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Industry perspectiv…
WOEHRLE Holger
MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is hear…
PRASAD Krishna
MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Different doses, differe…
VERHEUGT Freek
MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Non randomized and/…
POCOCK Stuart J.
MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is hear…
ZANNAD Faiez
MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : How to secure the optima…
GIBSON Michael
MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : How to secure the optima…
GELLER Nancy L.
MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 2 : Well Established Methods…
KOENIG Wolfgang
MODIGLIANI Workshop 2 - Friday November 30, 2012 : ATHEROSCLEROSIS IMAGING IN CLINICAL TRIALS Facilitating the discovery of effective therapies Chairpersons: Jagat NARULA, New York, USA - Ahmed
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Options of and alte…
ABRAHAM William T.
MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : Ultrafiltration fo…
ROSSI Gian Paolo
MODIGLIANI Debate Session 5 - Saturday December 1st, 2012 NOVEL DIURETIC STRATEGIES IN HEART FAILURE Chairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITA Webcast: Patrick
Sur le même thème
-
La naissance de la médecine scientifique (par Pierre Corvol)
CORVOL Pierre
MONTENOT Jean
La naissance de la médecine scientifique Dans La Maison Nuncingen (1837), Balzac met en scène une conversation entre quatre journalistes échauffés par un bon repas. L’un des commensaux, Émile
-
Prévention de l'accident vasculaire cérébral
Chaque année, en France, près de 125 000 cas d'AVC -- Accident Vasculaire Cérébral -- sont recensés. Avec les récidives, ce chiffre augmente de 25 % L' AVC représente la 1ère cause de handicap et
-
Michel Haïssaguerre, entre rythmes et musicalité
GLOINEC Yves
PRE Nadège
A l’occasion de la création de l’Institut Hospitalo-Universitaire LIRYC (Institut de Rythmologie et de Modélisation Cardiaque) dont il est à l’origine, le 2e volet de notre série Trip TIC
-
Du coté de chez...Michel Haïssaguerre
GLOINEC Yves
PRE Nadège
Inspiré du questionnaire de Proust, cet entretien plus intimiste engage une réflexion sur Michel Haïssaguerre en tant qu’homme et non plus en tant que cardiologue. Ce face-à-face permet de
-
Cardio-vasculaire
GAY Bernard
GOSSE Philippe
DOUARD Hervé
SASSOUST Gérard
Journées Bordeaux Segalen 2013 - Formation Médicale Continue des Médecins Généralistes - Session Cardio-vasculaire
-
Échocardiographie trans-œsophagienne
LAFITTE Stéphane
COTTARRE-LAFITTE Marianne
RéANT Patricia
ROUDAUT Raymond
Ce cours vidéo est tiré du cédérom Échocardiographie Doppler (éd. 2011), comportant plus de trente leçons (Écho-doppler transthoracique, Fonction systolique, Valvulopathies, Myocardiopathies,
-
Échocardiographie-Doppler normale
LAFITTE Stéphane
COTTARRE-LAFITTE Marianne
RéANT Patricia
ROUDAUT Raymond
Ce cours vidéo est tiré du cédérom Échocardiographie Doppler (éd. 2011), comportant plus de trente leçons (Écho-doppler transthoracique, Fonction systolique, Valvulopathies, Myocardiopathies,
-
Indications de l'ETO
LAFITTE Stéphane
COTTARRE-LAFITTE Marianne
RéANT Patricia
ROUDAUT Raymond
Ce cours vidéo est tiré du cédérom Échocardiographie Doppler (éd. 2011), comportant plus de trente leçons (Écho-doppler transthoracique, Fonction systolique, Valvulopathies, Myocardiopathies,
-
Rétrécissement mitral
LAFITTE Stéphane
COTTARRE-LAFITTE Marianne
RéANT Patricia
ROUDAUT Raymond
Ce cours vidéo est tiré du cédérom Échocardiographie Doppler (éd. 2011), comportant plus de trente leçons (Écho-doppler transthoracique, Fonction systolique, Valvulopathies, Myocardiopathies,
-
Dissection aortique
LAFITTE Stéphane
COTTARRE-LAFITTE Marianne
RéANT Patricia
ROUDAUT Raymond
Ce cours vidéo est tiré du cédérom Échocardiographie Doppler (éd. 2011), comportant plus de trente leçons (Écho-doppler transthoracique, Fonction systolique, Valvulopathies, Myocardiopathies,
-
Syndrome d'aorte douloureuse
LAFITTE Stéphane
COTTARRE-LAFITTE Marianne
RéANT Patricia
ROUDAUT Raymond
Ce cours vidéo est tiré du cédérom Échocardiographie Doppler (éd. 2011), comportant plus de trente leçons (Écho-doppler transthoracique, Fonction systolique, Valvulopathies, Myocardiopathies,
-
Hypertension artérielle
LAFITTE Stéphane
COTTARRE-LAFITTE Marianne
RéANT Patricia
ROUDAUT Raymond
Ce cours vidéo est tiré du cédérom Échocardiographie Doppler (éd. 2011), comportant plus de trente leçons (Écho-doppler transthoracique, Fonction systolique, Valvulopathies, Myocardiopathies,